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Introduction: This post hoc analysis evaluated the efficacy of indacaterol, a novel inhaled
once-daily long-acting b2-agonist, by disease severity (GOLD 2005) in patients with
moderate-to-severe COPD from six Asian countries/areas (Hong Kong, India, Japan, Korea,
Singapore, Taiwan).
Methods: Data from a 12-week, double-blind, placebo-controlled, parallel-group study in
patients randomized to indacaterol 150 mg, indacaterol 300 mg or placebo once daily were
analyzed based on baseline disease severity (moderate or severe). Endpoints were: trough
FEV1 (average of 23 h 10 min and 23 h 45 min post-dose values), transition dyspnoea index
(TDI) and St George’s Respiratory Questionnaire (SGRQ) at Week 12. Safety data were
collected.
Results: Of 347 patients randomized, 59.7% had moderate, and 40.3% had severe COPD. Least
squares means (LSMs) indacateroleplacebo differences in trough FEV1 at Week 12 exceeded
the pre-specified minimal clinically important difference (MCID) of 0.12L and were statistically03 323160; fax: þ44 1403 323054.
artis.com (N. Prasad).
2 Elsevier Ltd. All rights reserved.
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1716 Y. To et al.superior (p < 0.001) for indacaterol (150 mg, 300 mg) versus placebo in the two subgroups
[0.19L, 0.20L (moderate); 0.15L, 0.19L (severe) respectively]. LSM TDI scores for both indaca-
terol doses versus placebo in both subgroups were statistically superior (p < 0.05) and clini-
cally meaningful (1 unit). Both indacaterol doses showed improvements in LSM SGRQ total
scores at Week 12 which exceeded the MCID (4 units) versus placebo in both subgroups, with
indacaterol 300 mgeplacebo difference in the severe subgroup being statistically significant
(p < 0.01). Overall incidence of adverse events was lower with indacaterol than with placebo
across both subgroups.
Conclusions: Indacaterol demonstrated clinically relevant improvements versus placebo in
lung function, dyspnea and health status in Asian COPD patients irrespective of disease
severity.
Clinical Trials Identifier: NCT00794157.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation that is not fully reversible, is
usually progressive, and is associated with pathological
changes in the lungs. COPD is also associated with
a considerable economic and social burden.1 Based on the
current Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2011 strategy, patients with COPD are
assessed and classified into four different severity groups
based on the degree of airflow obstruction, symptoms and
rate of exacerbations. Based on the post-bronchodilator
forced expiratory volume in 1 s (FEV1) and FEV1/forced
vital capacity (FVC) < 0.70, patients are classified as mild
(FEV1 80% predicted), moderate (FEV1 50% and <80%
predicted), severe (FEV1 30% and <50% predicted) and
very severe (FEV1 <30% predicted) groups.
1
Inhaled long-acting bronchodilators are central to the
symptomatic management of COPD.1 In particular, long-
acting b2-agonists (LABAs) have been shown to improve
lung function, quality of life, symptoms and decrease the
rate of exacerbations.2
Long-acting muscarinic antagonists (LAMAs) inhaled
once-daily are used for regular maintenance treatment in
COPD, but should be used with caution in patients with
prostatic hypertrophy or glaucoma which are common in
the elderly.3 LABAs such as formoterol and salmeterol
require twice daily administration. Therefore, inhaled
bronchodilators available in the current market are not
enough to control the symptoms in COPD, indicating the
need for new bronchodilators.
Indacaterol, a novel, once-daily, inhaled ultra long-
acting b2-agonist
4 provides 24-h bronchodilation in
patients with COPD, with a fast onset after first dose.5e11
Indacaterol is approved in more than 60 countries world-
wide, including throughout the European Union,12 at doses
of 150 and 300 mg once-daily (od). It has been recently
approved in Japan at a dose of 150 mg od for the mainte-
nance treatment of COPD.
A recent multicenter, randomized, double-blind,
placebo-controlled, parallel-group study in patients with
moderate-to-severe COPD (NCT00794157) showed that,
compared with placebo, indacaterol 150 mg and 300 mg od
provided effective bronchodilation, with improvements ina range of patient reported outcomes (dyspnea, health
status) in a population with moderate-to-severe COPD from
six Asian countries/areas (Hong Kong, India, Japan, Korea,
Singapore, and Taiwan).11 In addition, both doses of inda-
caterol were associated with good overall safety and
tolerability profiles, consistent with the profiles observed in
other studies of up to 52 weeks duration.5,13
Since COPD is a heterogeneous disease,14 it is important
to understand how patients with different levels of disease
severity respond to a given therapy. This post hoc analysis
was conducted on data from the above study to determine
the response of patients with different disease severities
(moderate or severe) to indacaterol in doses 150 mg and
300 mg od.
Methods
Patients (males and females), aged 40 years, with
a smoking history of20 pack years, andpost-bronchodilator
FEV1 <80% and 30% (forced expiratory volume in 1 s) pre-
dicted and FEV1/FVC <70% (forced vital capacity) were
randomized (1:1:1) to indacaterol 150 or 300 mg od, or
matched placebo via a single-dose dry powder inhaler for 12
weeks. Additional details on the design of the study,
including concomitant medications used have been pub-
lished elsewhere.11 For the present post hoc analysis,
patients were grouped into two disease categories
(moderate [FEV1 50% and <80% predicted; FEV1/FVC
<0.70] or severe [FEV130% and <50% predicted; FEV1/FVC
<0.70]) according to their post-bronchodilator FEV1 at the
screening visit, using GOLD 200515 criteria. The study was
approved by the independent ethics committees or institu-
tional review boards of the participating centres, and was
conducted according the Declaration of Helsinki after
obtaining written informed consent from each patient.
Assessments
The superiority of indacaterol 150 mg or 300 mg to placebo
with respect to 24-h post-dose trough FEV1 (mean of FEV1
measurements at 23-h 10-min and 23-h 45-min post-dose)
after 12 weeks was analyzed in both the disease severity
subgroups. A treatment difference between indacaterol
Indacaterol is effective in Asian COPD population 1717and placebo of 0.12L in trough FEV1 was pre-specified as
a clinically important difference for COPD patients. Dysp-
nea was assessed after 12 weeks using the transition
dyspnoea index (TDI), with a difference from placebo of 1
unit regarded as the minimal clinically important differ-
ence (MCID).16 In addition, health status was assessed at
baseline and after 12 weeks in both the disease severity
subgroups using the St George’s Respiratory Questionnaire
(SGRQ) with the MCID being a difference from placebo of 4
units.17 Patients recorded their daily clinical symptoms i.e.,
percentages of nights with ‘no nighttime awakenings’ and
percentage of ‘days able to perform usual daily activities’
in electronic patient diaries.Statistical methods
Trough FEV1 after 12 weeks was analyzed using a mixed-
model containing treatment, disease severity, and
treatment-by-disease severity interaction as fixed effects,
with baseline FEV1 and FEV1 reversibility at screening as
covariates. The model also included smoking status and
country/area as fixed effects, with study centre nested
within country/area as a random effect. Data are reported
for each disease severity subgroup as least squares mean
(LSM) treatment effects and standard errors of the mean,
and as LSM treatment contrasts with 95% confidence
intervals (CIs). Similar mixed models were used for TDI totalTable 1 Patient demographics and baseline clinical characteris
Moderate COPDb [N Z 207]
Indacaterol
150 mg [n Z 73]
Indacaterol
300 mg [n Z 68]
Plac
[n Z
Age, years 65.4 (8.65) 67.8(7.83) 65.6
Male/female, % 94.5/5.5 95.6/4.4 92.4
Country, n (%)
Taiwan 12 (75.0) 11 (73.3) 7 (5
Indian 5 (38.5) 6 (46.2) 6 (4
Japanese 32 (64.0) 29 (55.8) 29 (
Korean 24 (75.0) 21 (63.6) 22 (
Other 0 1 (33.3) 2 (6
Duration of COPD,
years






51.3 (27.88) 54.3 (29.53) 48.1
ICS use, % 19.2 17.6 22.7
FEV1, L
a 1.68 (0.360) 1.63 (0.381) 1.63
FEV1, % predicted
a 63.1 (8.12) 62.4 (8.14) 60.9
FEV1/FVC, %
a 54.8 (8.65) 52.6 (8.18) 52.2
Reversibility to
salbutamol, %
13.6 (13.04) 13.8 (12.35) 14.7
COPD severity, n (%) 73 (100.0) 68 (100.0) 66 (
ICS Z inhaled corticosteroids; SD Z standard deviation.
a Post-salbutamol.
b Moderate COPD (FEV1 50% and <80% predicted; FEV1/FVC <0.70
c Severe COPD (FEV1 30% and <50% predicted; FEV1/FVC <0.70) [G
was calculated as % increase of FEV1 value after salbutamol relativ
otherwise stated.scores and SGRQ total and component scores, percentage
of nights with ‘no nighttime awakenings’ and percentage of
‘days able to perform usual daily activities’.
Results
Of a total of 519 screened patients, 347 were randomized,
and 308 (88.8%) completed the study. There was a higher
percentage of patients with moderate COPD than severe
COPD (59.7% versus 40.3%). The demographics and baseline
clinical characteristics for the randomized patients are
presented in Table 1.
Spirometry
At Week 12, the LSM indacateroleplacebo treatment
differences for trough FEV1 exceeded the pre-specified
MCID of 0.12L and were statistically significant in patients
with moderate or severe COPD (moderate: 0.19L and 0.20L
with indacaterol 150 and 300 mg, respectively; severe:
0.15L and 0.19L with indacaterol 150 and 300 mg, respec-
tively, p < 0.001 versus placebo for all comparisons)
(Fig. 1). In patients with moderate COPD, the mean changes
from baseline (% change from baseline) in trough FEV1 at
Week 12 were 130 mL (10%) with indacaterol 150 mg, 160 mL
(13%) with indacaterol 300 mg and 50 mL (3%) with
placebo. The mean changes from baseline in trough FEV1 intics.




150 mg [n Z 41]
Indacaterol
300 mg [n Z 48]
Placebo
[n Z 51]
(9.04) 68.2 (8.73) 66.1 (7.39) 67.6 (8.29)
/7.6 100/0 100/0 100/0
0.0) 4 (25.0) 4 4 (26.7) 7 (50.0)
0.0) 8 (61.5) 7 (53.8) 9 (66.0)
58.0) 18 (36.0) 23 (44.2) 21 (42.0)
62.9) 8 (25.0) 12 (36.4) 13 (37.1)
6.7) 3 (100.0) 2 (66.7) 1 (33.3)
(4.12) 4.2(3.29) 4.1(4.11) 4.3 (3.78)
/30.3 73.2/26.8 68.8/31.3 76.5/23.5
(28.29) 52.5 (31.80) 53.7 (27.43) 51.7 (27.67)
26.8 27.1 37.3
(0.312) 1.07 (0.199) 1.09 (0.189) 1.05 (0.196)
(7.50) 41.2 (5.21) 41.4 (5.99) 41.2 (5.94)
(9.34) 42.1 (8.52) 43.3 (8.85) 41.9 (8.74)
(12.24) 16.8 (12.48) 17.3 (17.75) 16.0 (13.10)
100.0) 41 (100.0) 48 (100.0) 51 (100.0)
) [GOLD 2005].
OLD 2005]. FEV1 reversibility after inhalation of 400 mg salbutamol
e to FEV1 value before salbutamol. Data are mean (SD) unless
Figure 1 Least squares mean (95% CI) treatment differences versus placebo in trough FEV1 (L) at Week 12 (ITT population). The
dotted line indicates the pre-specified level of clinical relevance. FEV1 Z forced expiratory volume in 1 s; ITT Z intent-to-treat;
Ind Z indacaterol. ***p < 0.001 versus placebo.
1718 Y. To et al.patients with severe COPD at Week 12 were 120 mL (13%)
with indacaterol 150 mg, 140 mL (15%) with indacaterol
300 mg and 60 mL (5.5%) with placebo.
Dyspnea
The LSM TDI total scores in both disease severity subgroups
at Week 12 for both indacaterol doses were statistically
superior (p < 0.05) and clinically meaningful (1 unit)
versus placebo (Table 2).
Health status
In patients with moderate COPD, for both indacaterol
doses, the LSM difference from placebo in SGRQ total score
at Week 12 exceeded the MCID of 4 units (4.3 and 4.2
units for indacaterol 150 mg and 300 mg, respectively;
Fig. 2a). The LSM differences from placebo in SGRQ total
score in patients with severe disease also exceeded MCID of
4 units (5.5 and 7.9 for indacaterol 150 mg and 300 mg,
respectively), reaching statistical significance for the
300 mg dose (p < 0.01, Fig. 2b). In addition, all SGRQ
component scores decreased (i.e., health status improved)
compared with placebo in both the disease severity
subgroups with both doses of indacaterol. In the severe
subgroup, the symptoms scores were statistically superior
(p < 0.05) with indacaterol 300 mg compared with placebo.Table 2 Least squares mean (95% CI) treatment differences ve
Moderate
Indacaterol
150 mg e Placebo
Indac
300 m
TDI total score, LSM (95% CI) 1.15 (0.27, 2.03)a 1.16
CI Z confidence interval, ITT Z intent-to-treat; TDI Z transition dy
a p < 0.05.
b p < 0.01 versus placebo (within subgroup).The impact scores reached statistical significance
(p < 0.05) with both indacaterol doses versus placebo in the
severe COPD subgroup (Fig. 2a and b).
Diary data
The percentages of ‘nights with no nighttime awakenings’,
and percentages of ‘days able to perform usual daily
activities’ improved in both disease severity subgroups with
both doses of indacaterol compared with placebo (Table 3).
Numerical improvements versus placebo in diary data were
also seen with both indacaterol doses in patients with
severe COPD, attaining statistical significance (p < 0.05)
with indacaterol 300 mg for percentage of ‘days able to
perform usual daily activities’ (Table 3).
Safety
The incidence of adverse events (AEs) was comparable for
both indacaterol doses (43.9e56.3%) with placebo
(58.8e59.1%). The incidences are comparable to what has
been reported for the entire study population.11 The most
common AEs reported for indacaterol 150 mg, indacaterol
300 mg and placebo in patients with moderate COPD were
COPD worsening (6.8, 7.4 and 12.1%, respectively) followed
by nasopharyngitis (9.6, 4.4 and 12.1%, respectively). In





150 mg e Placebo
Indacaterol
300 mg e Placebo
(0.27, 2.05)a 1.53 (0.42, 2.63)b 1.39 (0.31, 2.47)a
spnoea index; LSM Z least squares mean.
Figure 2 Least squares mean (95% CI) treatment differences versus placebo in SGRQ total score, symptoms, activity and impacts
component scores data at Week 12 (ITT population). The dotted line indicates the pre-specified level of clinical relevance. Data are
least squares mean with 95% confidence intervals (LSM [95% CI]); ITT Z intent-to-treat; SGRQ Z St. George’s Respiratory Ques-
tionnaire; Ind Z indacaterol. *p < 0.05, **p < 0.01 versus placebo.
Indacaterol is effective in Asian COPD population 1719AEs for indacaterol 150 mg, indacaterol 300 mg and placebo
were cough (4.9, 16.7 and 3.9%, respectively) and COPD
worsening (14.6, 12.5 and 13.7%, respectively). Overall, AEs
were mostly mild to moderate in severity and no deaths
were reported during the study.Discussion
This post hoc analysis was primarily conducted to confirm the
efficacy and safety of indacaterol 150 mg and 300 mg od in
Asian patients with moderate or severe COPD. A subgroup
analysis based on disease severity was performed toadditionally evaluate if patients with varying degrees of
disease severity respond differently to indacaterol. Both the
doses of indacaterol provided statistically significant
(p < 0.001) and clinically relevant (exceeding the MCID of
0.12L) bronchodilation versus placebo (in terms of trough
FEV1) in both disease severity subgroups. Non-statistically
significant but numerically greater improvements in trough
FEV1 were observed with the higher dose of indacaterol in
patients with severe COPD comparedwith indacaterol 150 mg
(treatment difference of 20mL in themoderate subgroupand
30mL in the severe subgroup). Previous studies of indacaterol
in patients with moderate-to-severe COPD from Asian11 and
Caucasian populations5e8 have shown that indacaterol 150mg
Table 3 Least squares mean (95% CI) treatment differences versus placebo in percentages of nights with ‘no nighttime
awakenings’ and percentages of ‘days able to perform usual daily activities’ over 12 weeks.
LSM (95% CI) Moderate Severe
Indacaterol
150 mg e Placebo
Indacaterol
300 mg e Placebo
Indacaterol
150 mg e Placebo
Indacaterol
300 mg e Placebo
Percentage of nights ‘with no
nighttime awakenings’
11.1 (2.9, 19.4)b 9.0 (0.7, 17.2)a 2.0 (8.3, 12.2) 7.2 (2.6, 16.9)
Percentage of ‘days able to
perform usual daily activities’
18.9 (9.7, 28.0)c 22.1 (12.9, 31.4)c 7.9 (3.1, 18.9) 12.7 (1.9, 23.5)a
LSM Z least squares mean; CI Z confidence interval.
a p < 0.05.
b p < 0.01.
c p < 0.001 versus placebo (within subgroup).
1720 Y. To et al.and indacaterol 300 mg od significantly improved trough FEV1
at 12 weeks compared with placebo.
In addition to improvements in lung function, both
indacaterol doses showed clinically relevant and statisti-
cally significant improvements (p < 0.05) in dyspnea
compared with placebo in both subgroups. Patients with
COPD often experience dyspnea that impacts daily activi-
ties and quality of life1 irrespective of disease severity.18
The severity of dyspnea increases with increasing disease
severity.1 It is therefore very beneficial to note that both
indacaterol doses showed clinically relevant improvements
in TDI in patients irrespective of disease severity.
Improvements versus placebo in dyspnea were previously
seen with indacaterol in patients with moderate-to-severe
COPD5,6,8 and irrespective of disease severity.19
As the disease progresses, patients with COPD experience
increasing deterioration in their health-related quality of
life (HRQoL).20 Therefore, an important outcome of clinical
interventions for COPD is the improvement in the health
status. In the current study, both doses of indacaterol
provided clinically meaningful improvements (i.e., 4 units
reduction in total score) in health status compared with
placebo in both disease severity subgroups. However,
limited conclusions can be drawn from these data as the only
difference from placebo to reach statistical significance was
for the 300 mg dose in the severe group. Improvements were
seen in the individual component scores of SGRQ with both
indacaterol doses and in both the disease severity
subgroups; the results were statistically significant for the
symptoms and impacts components in the severe COPD
subgroup receiving higher dose of indacaterol. Previous
long-term trials with indacaterol showed significantly
improved health-related quality of life with both indacaterol
doses of 150 mg and 300 mg od as well as each component
score, compared with placebo.5,6,8 This could be due to the
lower baseline SGRQ scores in the current study indicating
better health status at baseline than in the previous inda-
caterol studies. Given the lack of statistical significance,
limited conclusions can be drawn from these data; never-
theless, the consistent numerical trends suggest that both
doses of indacaterol provided effective improvements in
health status regardless of baseline disease severity.
Nighttime awakenings21 and impaired performance in
daily activities1 have substantial impacts on the ability of
patients with COPD to lead a normal life. The improvementsseen in the percentages of ‘nights with no nighttime awak-
enings’, and percentages of ‘days able to perform usual daily
activities’ with both indacaterol doses in both disease
severity subgroups indicate that indacaterol could have
a useful role in managing symptoms in COPD patients across
a range of disease severities.
Both indacaterol doses were well tolerated, with a lower
incidence of AE than placebo. Given the relatively short
duration of the current study, no definite conclusions can be
drawn on the safety of indacaterol from these data alone
because a 12-week study may not identify all safety signals
associated with an intervention. Safety of indacaterol data
are available from longer term studies, including a 12-month
study that recruited patients from Japan only,22 and studies
in Caucasian populations of up to 12-months5 duration along
with a pooled safety analysis.23 These longer term studies
provide supportive evidence of the safety of indacaterol.
Most indacaterol clinical trials have analyzed the effi-
cacy and safety of indacaterol in patients with moderate-
to-severe COPD.5e8,11 Since COPD is a heterogeneous
disease14 it is beneficial to assess if the efficacy of inda-
caterol is maintained in patients with different disease
severities. Results of the current study conducted primarily
in an Asian population showed that indacaterol can be
effective in the management of either moderate or severe
COPD. This is substantiated by an analysis of pooled data
from three pivotal indacaterol studies conducted in
Caucasian populations which showed improved FEV1 and
clinical outcomes after 6 months of indacaterol (150 mg and
300 mg) treatment by a significant margin over placebo,
irrespective of COPD severity.19
In conclusion, this all-Asian study in patients with COPD
demonstrated that indacaterol provided clinically relevant
bronchodilation and improvement in clinical outcomes over
placebo irrespective of disease severity. There were no
significant differences between the two indacaterol doses
in improving trough FEV1, TDI score and SGRQ score in both
the moderate and severe disease subgroups.Conflict of Interest
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